Commercial-ready GRAS peptide for oral weight management
LLS Peptide is a proprietary, GRAS tripeptide for effective weight management by inhibiting aldolase in adipocytes. It's water-soluble, tasteless, and stable, ideal for beverages, with proven efficacy in reducing body weight gain and improving metabolic health.
Overview
LLS Peptide is a scientifically proven, proprietary GRAS tripeptide designed for oral weight management. By targeting aldolase, a glycolytic enzyme that contributes to fat accumulation in adipocytes, LLS Peptide offers a novel approach to weight control. Unlike current treatments, it disrupts de novo lipogenesis directly at the source, leading to reduced lipid accumulation, smaller fat cells, and improved metabolic parameters. Its water-soluble, tasteless, and stable nature makes it particularly suitable for integration into beverages and functional foods.
Technical specifications
Key features:
- Aldolase Inhibition: Specifically blocks aldolase activity in adipocytes to prevent sugar-to-fat conversion.
- Efficacy: Achieves a 30% reduction in body weight gain, a 30% increase in HDL/LDL ratio, a 12% reduction in adipocyte size, over 60% reduction in intracellular fat, and a 15% reduction in blood glucose levels.
- Formulation Flexibility: Available in water-soluble, tasteless forms ideal for beverages.
- GRAS Status: Recognized as safe for consumption and ready for commercial formulation.
Technology readiness level
This technology is at TRL 8, indicating it is fully validated in preclinical settings and is transitioning towards commercialization. Future steps include formulation optimization, consumer validation, and preparation for pilot-scale production.
About Lean Life Sciences, INC
Lean Life Sciences, Inc. is a life sciences company focused on the development of highly effective anti-obesity supplements. The company aims to provide therapeutic alternatives that avoid the significant health risks and severe side effects often associated with existing anti-obesity pharmacological treatments.
This development is significant for customers and partners in the healthcare sector, particularly in the underserved obesity treatment market. By prioritizing safety alongside therapeutic efficacy, Lean Life Sciences seeks to improve patient outcomes and address critical gaps in current obesity management. The company is currently recognized as an active entity with technological development linked to university-affiliated research institutions.
delivered to your inbox.